Fingolimod for multiple sclerosis

Drug and Therapeutics Bulletin

Volumn 50, Issue 2, 2012, Pages 18-20

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GADOLINIUM; PLACEBO;

ARTICLE; ATRIOVENTRICULAR BLOCK; BACKACHE; BRADYCARDIA; BRAIN RADIOGRAPHY; COUGHING; DIARRHEA; DISEASE ACTIVITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS; HUMAN; IMMUNE DEFICIENCY; INFLUENZA; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; RETINA MACULA EDEMA; SIDE EFFECT; TERATOGENICITY; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG COSTS; DRUG INFORMATION SERVICES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84857133005     PISSN: 00126543     EISSN: 17555248     Source Type: Journal    
DOI: 10.1136/dtb.2012.02.0086     Document Type: Article

References (17)

1. Glatiramer acetate for multiple sclerosis. DTB 2001; 39: 41-3.
2. Compston A et al. Multiple sclerosis. Lancet 2002; 359: 1221-31.
3. Interferon beta-1b - hope or hype? DTB 1996; 34: 9-11
4. Interferon beta-1a for multiple sclerosis. DTB 1998; 36: 7-8.
5. Natalizumab for muliple sclerosis? DTB 2008; 46: 69-72
6. Scolding N. The multiple sclerosis risk sharing scheme. BMJ 2010; 340: c2882.
7. Department of Health, 2011. Multiple sclerosis risk sharing scheme [online]. Available: http://www.dh.gov.uk/en/Healthcare/Medicinespharmacyandindustry/Prescriptions/Costeffectiveprescribing/DH_123794 [Accessed 19 January 2012].
8. National Institute for Health and Clinical Excellence, 2007. Natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis. TAG 127 [online]. Available: http://www.nice.org.uk/nicemedia/live/11822/36136/36136.pdf [Accessed 19 January 2012].
9. Gilenya 0.5mg hard capsule. Summary of product characteristics, EU. Novartis, March 2011.
10. Mehling M et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011; 76(8 Suppl 3): S20-7.
11. Kappos L et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
12. Cohen JA et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
13. European Medicine Agency, 2011. Assessment report - Gilenya [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_ assessment_report/human/002202/WC500104529.pdf [Accessed 19 January 2012].
14. European Medicines Agency, 2011. Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the member states [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Conditions_imposed_on_member_states_for_safe_and_effective_use/human/002202/WC500104527.pdf [Accessed 19 January 2012].
15. Greater Manchester Medicines Management Group, 2011. Fingolimod [online]. Available: http://www.nyrdtc.nhs.uk/GMMMG/Groups/Publications/GM_NDE/GM_NDE_38_Fingolimod.pdf [Accessed 19 January 2012].
16. National Institute for Health and Clinical Excellence, 2012. Multiple sclerosis (relapsing-remitting) - fingolimod [online]. Available: http://guidance.nice.org.uk/TA/Wave20/71 [Accessed 19 January 2012].
17. Scottish Medicines Consortium, 2012. Forthcoming submission: fingolimod (Gilenya). Available: http://www.scottishmedicines.org.uk/SMC_Advice/Forthcoming_ Submission: fingolimod_(Gilenya) [Accessed 19 January 2012].